During our project, we generated multiple basic and composite parts, and characterized and improved some existing parts. We created Cytolysin A (Y171F) (BBa_K4359001) an attenuated version of Cytolysin A for future teams to safely work with. We added to the characterization of the myc tag (BBa_K823036), and demonstrated that anti myc antibodies cross react with endogenous c-myc present in many mammalian cell lines, making it incompatible for use with such systems.
| Name | Type | Description | Length |
|---|---|---|---|
| BBa_K4359000 | Coding Protein | E.coli K-12 Cytolysin A (ClyA) | 1008 bp |
| BBa_K4359001 | Coding Protein | E.coli K-12 Cytolysin A (ClyA) (Y181F) | 930 bp |
| BBa_K4359002 | Coding Protein | Anti-HER2 Affibody-ZHER2:342 | 177 bp |
| BBa_K4359003 | Coding Protein | (SSSSG) x2 serine glycine linker | 30 bp |
| BBa_K4359004 | Coding Protein | Tumor homing peptide THP Pep-1 against SKBR3 | 30 bp |
| BBa_K4359007 | Epitope Tag | V5 tag | 42 bp |
| Name | Description | Length |
|---|---|---|
| BBa_K4359006 | ClyA-Myc-Affi | 1245 bp |
| BBa_K4359008 | ClyA-V5-Affi | 1281 bp |
| BBa_K4359009 | ClyA-3XFLAG-THP | 1134 bp |
As a team, we are very passionate about OMVs and their potential in diverse fields of biomedical research. We performed extensive literature review regar̥ding the composition, biogenesis, bioengineering of OMVs and their applications in vaccines, as adjuvants, and diagnostics. We wanted to collate this information and present an OMV handbook that can be used as a reference by iGEM teams and other researchers in the future.